ViewRay Meets Primary Endpoint for Ablative Doses of Radiation to Pancreatic Cancer

 Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART

ViewRay, Inc. (NASDAQ: VRAY) announced today that the findings from the first Phase II prospective international multi-institutional study to deliver ablative doses of radiation to pancreatic cancer patients will be presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio. The results will be featured as part of the Special Session of Late-Breaking Abstracts and will take place on Tuesday, October 25, at 3:00 p.m. Central Time. The data will be presented by Parag Parikh, M.D., study's principal investigator and Director of GI Radiation Oncology and MR-Guided Radiation Therapy at the Henry Ford Cancer Institute in Detroit.

https://www.biospace.com/article/releases/viewray-announces-primary-endpoint-outcome-from-first-prospective-multi-institutional-study-to-deliver-ablative-doses-of-radiation-to-pancreatic-cancer-patients/